The PTAB recently instituted a second IPR of US Patent 9,296,821 (“the ’821 patent”), which covers certain uses of Rituxan®...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
BiosimilarsIP.com News section provides updates on current news and events related to biologics and biosimilars.
-
-
U.S. Patent No. 8,329,172 (“the ’172 patent”), a Biogen-owned patent covering a treatment regime for low-grade B-cell non-Hodgkin’s...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On July 2, 2018, Genentech filed suit against Eli Lilly and Company (“Lilly”) in the Southern District of California alleging Lilly’s...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
As we previously reported here and here, Celltrion filed suit against Genentech seeking declaratory judgment that a host of patents...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Earlier this month, the U.S. FDA announced approval of Mylan’s Fulphila biosimilar to Neulasta® (pegfilgrastim). Neulasta® was...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
The Patent Trial and Appeal Board (“PTAB”) recently denied Sandoz’s petition for inter partes review (“IPR”) of claims 1-30 of...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Last week, Eli Lilly and Company (“Lilly”) announced that galcanezumab met its primary endpoint in a Phase 3 study of patients with...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]